Boston Scientific Corporation announced a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical‑technology company that develops the eCoin® System, a coin‑sized implantable device that delivers intermittent tibial nerve stimulation to treat urgency urinary incontinence. The deal, announced on January 12, 2026, will add the eCoin system to Boston Scientific’s urology portfolio and broaden its presence in the overactive bladder market, which serves nearly 30 million U.S. adults.
The eCoin® System received FDA approval in 2022 and demonstrated a 68 % rate of at least a 50 % reduction in urge urinary incontinence episodes in pivotal trials. By acquiring Valencia, Boston Scientific gains a minimally invasive, implantable neuromodulation platform that complements its existing pelvic‑health products, such as the AMS 800 artificial urinary sphincter. The transaction is described as a “high‑growth adjacency” that will allow the company to offer a more comprehensive set of treatment options across the care continuum.
Financially, Boston Scientific expects the acquisition to have an immaterial impact on adjusted earnings per share in 2026 while being more dilutive on a GAAP basis. The deal value was not disclosed, but the company indicated that the transaction will close in the first half of 2026, subject to customary closing conditions. Boston Scientific’s recent quarterly results—net revenue of $5,065 million and 15.3 % year‑over‑year organic growth in the third quarter—illustrate the strength of its urology segment and the strategic fit of the eCoin system.
Boston Scientific’s overall revenue grew 21.61 % over the last twelve months, reaching $19.35 billion, and the company’s urology business has been a key driver of that growth. The addition of Valencia’s technology positions Boston Scientific to capture a larger share of the tibial nerve stimulation market, which is expected to expand as clinicians seek less invasive alternatives to traditional catheter‑based therapies.
The overactive bladder market faces competition from other neuromodulation devices, such as the Medtronic Peristek and the Boston Scientific’s own existing implantable options. By integrating the eCoin system, Boston Scientific can differentiate its product line with a smaller, coin‑sized device that offers a less invasive implantation near the ankle, potentially improving patient acceptance and expanding its market reach.
Meghan Scanlon, senior vice president and president of Urology at Boston Scientific, said the acquisition “will enable us to expand into implantable tibial nerve stimulation, a high‑growth adjacency for our Urology business. ITNS technology complements our existing pelvic health product line, and we look forward to offering a more comprehensive set of treatment options to patients across the care continuum.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.